A specific pole placement technique to minimise hardware requirements within a real time terrestrial and cable video echo canceller

The real time hardware architecture of a deterministic video echo canceller (deghoster) system is presented. The deghoster is capable of calculating all the multipath channel distortion characteristics from terrestrial and cable television in one single pass while performing real time video in-line ghost cancellation. The results from the actual system are also presented in this paper.

Ensaio clínico fase III para Leishmaniose Tegumentar Americana forma cutâneaequivalência entre esquemas de alta e baixa dose de antimoniato de meglumina

Neste estudo comparamos esquemas de alta e baixa dose de antimoniato de meglumina (AM) para o tratamento da forma cutânea de leishmaniose tegumentar americana, em pacientes oriundos do estado do Rio de Janeiro. OBJETIVO: Comparar a eficácia representada pela cura imediata (epitelização em 120 dias), tardia (cicatrização em 360 dias) e definitiva (ausência de reativação ou lesão mucosa em 720 dias) e toxicidade (clínica, laboratorial e eletrocardiográfica) com duas diferentes doses de tratamento com AM para leishmaniose cutânea (LC) e comparar os critérios de cura clínica aqui adotados com aqueles estabelecidos pelo Ministério da Saúde. MÉTODO: Ensaio clínico de não inferioridade, controlado, randomizado, cego e de fase III, com 60 pacientes com LC alocados em dois grupos de tratamento: (A) 20mg Sb5+/kg/dia por 20 dias e (B) 5mg Sb5+/kg/dia por 30 dias administrados por via intramuscular. RESULTADOS: Pacientes dos grupos A e B apresentaram, respectivamente: Cura imediata 90,0% e 86,7%, com tempo médio de epitelização de 58,7 e 54,9 dias; cura tardia por intenção de tratar 76,7% e 73,3%; e cura tardia por análise de protocolo 84,6% e 75,9%. Dos 53 pacientes que apresentaram epitelização em até 120 dias, 44 (83,4%) evoluíram para cura tardia. Quando avaliados conjuntamente, os efeitos adversos (EA) clínicos, laboratoriais e eletrocardiográficos foram mais frequentes no grupo A que no grupo B (médias 7,9 e 4,7) e mais graves [RR= 2,22 (IC 95% 1,22-4,06) p=0,0045] no grupo A. Os EA clínicos graus 2 e 3 foram mais frequentes no grupo A; RR=6,5 (IC 95% 1,60-26,36) p=0,001 Os EA laboratoriais foram mais frequentes RR=1,39 (IC 95% 0,99-1,93) p=0,05 e mais graves (graus 2, 3 ou 4) RR=4,67 (IC 95% 1,49-14,59) p=0,0016 no grupo A. Hiperlipasemia foi a alteração laboratorial mais frequente e mais grave. Pacientes do grupo A apresentaram um RR=4,0, p=0,006 de desenvolver hiperlipasemia moderada a grave, com fração atribuível de 75%. Dez pacientes (16,7%) necessitaram suspender o tratamento temporariamente por apresentarem QTc >0,46ms, entretanto não houve diferença entre os grupos.CONCLUSÃO: A dose de 5mg Sb5+/kg/dia mostrou-se menos tóxica, mais segura e de menor custo no tratamento da LC, especialmente em idosos e pacientes com co-morbidades, atualmente com restritas opções terapêuticas. Entretanto, a hipótese de não inferioridade da dose baixa em relação a dose alta não pôde ser comprovada A epitelização com 120 dias, seguida de progressiva melhora no sentido da cicatrização em 360 dias sugere um possível benefício com a flexibilização dos critérios de cura da LC

A method for assessing confidence in requirements analysis

Context: During development managers, analysts and designers often need to know whether enough requirements analysis work has been done and whether or not it is safe to proceed to the design stage. Objective: This paper describes a new, simple and practical method for assessing our confidence in a set of requirements. Method: We identified 4 confidence factors and used a goal oriented framework with a simple ordinal scale to develop a method for assessing confidence. We illustrate the method and show how it has been applied to a real systems development project. Results: We show how assessing confidence in the requirements could have revealed problems in this project earlier and so saved both time and money. Conclusion: Our meta-level assessment of requirements provides a practical and pragmatic method that can prove useful to managers, analysts and designers who need to know when sufficient requirements analysis has been performed.

‘Some Misconceptions about Requirements for the Post-2013 CAP’, ‘Supplementary written evidence’, and minutes of evidence of 19 January

Written evidence, and minutes of evidence, to the House of Commons Select Committee on Environment, Food and Rural Affairs enquiry into The Common Agricultural Policy after 2013

The dose rate debate: does the risk of fungicide resistance increase or decrease with dose?

This paper reviews the evidence relating to the question: does the risk of fungicide resistance increase or decrease with dose? The development of fungicide resistance progresses through three key phases. During the ‘emergence phase’ the resistant strain has to arise through mutation and invasion. During the subsequent ‘selection phase’, the resistant strain is present in the pathogen population and the fraction of the pathogen population carrying the resistance increases due to the selection pressure caused by the fungicide. During the final phase of ‘adjustment’, the dose or choice of fungicide may need to be changed to maintain effective control over a pathogen population where resistance has developed to intermediate levels. Emergence phase: no experimental publications and only one model study report on the emergence phase, and we conclude that work in this area is needed. Selection phase: all the published experimental work, and virtually all model studies, relate to the selection phase. Seven peer reviewed and four non-peer reviewed publications report experimental evidence. All show increased selection for fungicide resistance with increased fungicide dose, except for one peer reviewed publication that does not detect any selection irrespective of dose and one conference proceedings publication which claims evidence for increased selection at a lower dose. In the mathematical models published, no evidence has been found that a lower dose could lead to a higher risk of fungicide resistance selection. We discuss areas of the dose rate debate that need further study. These include further work on pathogen-fungicide combinations where the pathogen develops partial resistance to the fungicide and work on the emergence phase.

A note on estimating market–based minimum capital risk requirements: a multivariate GARCH approach

Internal risk management models of the kind popularized by J. P. Morgan are now used widely by the world’s most sophisticated financial institutions as a means of measuring risk. Using the returns on three of the most popular futures contracts on the London International Financial Futures Exchange, in this paper we investigate the possibility of using multivariate generalized autoregressive conditional heteroscedasticity (GARCH) models for the calculation of minimum capital risk requirements (MCRRs). We propose a method for the estimation of the value at risk of a portfolio based on a multivariate GARCH model. We find that the consideration of the correlation between the contracts can lead to more accurate, and therefore more appropriate, MCRRs compared with the values obtained from a univariate approach to the problem.

An extreme value theory approach to calculating minimum capital risk requirements

This paper investigates the frequency of extreme events for three LIFFE futures contracts for the calculation of minimum capital risk requirements (MCRRs). We propose a semiparametric approach where the tails are modelled by the Generalized Pareto Distribution and smaller risks are captured by the empirical distribution function. We compare the capital requirements form this approach with those calculated from the unconditional density and from a conditional density - a GARCH(1,1) model. Our primary finding is that both in-sample and for a hold-out sample, our extreme value approach yields superior results than either of the other two models which do not explicitly model the tails of the return distribution. Since the use of these internal models will be permitted under the EC-CAD II, they could be widely adopted in the near future for determining capital adequacies. Hence, close scrutiny of competing models is required to avoid a potentially costly misallocation capital resources while at the same time ensuring the safety of the financial system.